

proaches that might be considered as preventive or therapeutic interventions in IDDM.

JEFFREY L. MAHON, FRCP  
JOHN DUPRÉ, FRCP  
CALVIN R. STILLER, FRCP  
ALLAN P. DONNER, PhD

REFERENCES

1. Stiller CR, Dupré J, Gent M, Jenner MR, Keown PA, Lupacis A, Martell R, Rodger NW, von Graffenried B, Wolfe BMJ: Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. *Science* 223:1362-67, 1984
2. Assan R, Debray-Sachs M, Laborie C, Chatenoud L, Feutren G, Quinion-Debrie MC, Thomas G, Bach JF: Metabolic and immunological effects of cyclosporin in recently diagnosed type I diabetes mellitus. *Lancet* 1:67-71, 1985
3. Feutren G, Papoz L, Assan R, Vialettes B, Karsenty G, Vexiau P, Du Rostu H, Rodier M, Sirmaj J, Lallemand A, Bach JF: Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset: results of multicenter double-blind trial. *Lancet* 2:119-24, 1986
4. The Canadian-European Randomized Control Trial Group: Cyclosporin-induced remission of IDDM after early intervention: association of 1 yr of cyclosporin treatment with enhanced insulin secretion. *Diabetes* 37:1574-82, 1988
5. Dorman JS, LaPorte RE, Kuller LH, Cruickshanks KJ, Orchard TJ, Wagener DK, Becker DJ, Cavender DE, Drash AL: The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study: mortality results. *Diabetes* 33:271-76, 1984
6. Snedecor GW, Cochran WG: *Statistical Methods*. Ames, Iowa State Univ. Press, 1980, p. 129
7. Cryer PE, Binder C, Bolli GB, Cherrington AD, Gale EAM, Gerich JE, Sherwin RS: Hypoglycemia in IDDM. *Diabetes* 38:1193-99, 1989
8. The DCCT Research Group: The Diabetes Control and Complications Trial (DCCT): design and methodologic considerations for the feasibility phase. *Diabetes* 35:530-45, 1986
9. Miescher PA, Favre H, Chatelanat F, Mihatsch M: Combined steroid cyclosporin treatment of chronic autoimmune diseases. *Klin Wochenschr* 65:727-36, 1987
10. Bougneres PF, Carel JC, Castano L, Boitard C, Gardin JP, Landacs P, Hors J, Mihatsch MJ, Paillard M, Chaussain JL, Bach JF: Factors associated with early remission of type I diabetes in children treated with cyclosporine. *N Engl J Med* 318:663-70, 1988
11. The DCCT Research Group: Effects of age, duration, and treatment of IDDM on residual beta-cell function: observations during eligibility testing for the DCCT. *J Clin Endocrinol Metab* 65:30-36, 1987
12. Agner T, Damm P, Binder C: Remission in IDDM: prospective study of basal C-peptide and insulin dose in 268 consecutive patients. *Diabetes Care* 10:164-69, 1987
13. Clarson C, Daneman D, Drash AL, Becker DJ, Ehrlich RM: Residual  $\beta$ -cell function in children with IDDM: reproducibility of testing and factors influencing secretory reserve. *Diabetes Care* 10:33-38, 1987
14. Kaar ML, Akerblom HK, Huttenen NP, Knis M, Sakkinen P: Metabolic control in children and adolescents with IDDM. *Acta Paediatr Scand* 73:102-108, 1984
15. Vague P, Pico R, Bernal M, Lassmann-Vague V, Vialettes B: Effect of nicotinamide treatment on the residual insulin secretion in type I diabetic patients. *Diabetologia* 32:316-21, 1989
16. Sjoberg S, Gunnarsson R, Gjotterberg M, Lefvery AK, Persson A, Ostman J: Residual insulin production, glycemic control and prevalence of microvascular lesions and polyneuropathy in long-term type I diabetes mellitus. *Diabetologia* 30:208-13, 1987
17. Eff C, Faber O, Deckert T: Persistent insulin secretion assessed by plasma C-peptide estimation in long-term juvenile diabetics with a low insulin requirement. *Diabetologia* 15:169-72, 1978
18. Bires B, Follansbee W, Orchard T: Does residual  $\beta$ -cell function relate to the complications of IDDM (Abstract)? *Diabetes* 38 (Suppl. 2):127A, 1989
19. Jackson R, Vardi P, Herskowitz R, Soeldner JS, Eisenbarth GS: Dual parameter linear model for prediction of onset of type I diabetes in islet cell antibody positive relatives (Abstract). *Clin Res* 36:585A, 1988
20. Dupré J, Stiller CR, Jenner M, Mahon J, Keown P, Rodger NW, Wolfe BM: Responses to nutrients in non-insulin requiring (NIR) remission of type I diabetes during administration of cyclosporin (Abstract). *Diabetes* 36 (Suppl. 1):74A, 1987
21. The DCCT Research Group: Diabetes Control and Complications Trial (DCCT): results of feasibility study. *Diabetes Care* 10:1-19, 1987

Southerly Migration

The July issue of *Diabetes Care* marks an important change in both the personality and geography of the journal. The editorial offices have been moved from Vermont and are now located at the Medlantic Research Foundation in Washington, DC. Like a faithful pet, *Diabetes Care* followed me on sabbatical leave to the laboratories of Drs. Ngoc Anh-Le, Barbara Howard, and Virgil Brown.

It is a great pleasure to welcome Drs. Richard East-

man, Maureen Harris, Barbara Howard, Jim Howard, and Bob Silverman as associate editors. These individuals are well known for their work in the areas of atherosclerosis, lipoprotein metabolism, substrate metabolism, clinical diabetes, clinical trials, and epidemiology. They bring new areas of expertise and a change in personality to the editorial committee.

I leave behind and will miss the four Vermont-based friends and associate editors and the energetic and scin-

tillating Wednesday editorial meetings we shared. Jorge Calles-Escandon, Ken Copeland, John Devlin, and Richard Tonino were extremely conscientious, scholarly, and dedicated editors. They gave many, many hours of their precious time to the journal.

From a practical point of view, authors, reviewers, and correspondents should note the new Washington, DC, address, telephone, and fax numbers shown on the journal masthead and our stationery. The move has

been carefully orchestrated to ensure a smooth transition and avoid any delay in the review process.

Finally, I want to thank Angela Patten, our interim editorial assistant in Vermont, and the publications staff of the American Diabetes Association who have been extremely helpful in facilitating this move and making it nearly effortless.

D.C.R.